Cargando…

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

Detalles Bibliográficos
Autores principales:	Swaminathan, Mahesh, Ravandi, Farhad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543186/ https://www.ncbi.nlm.nih.gov/pubmed/37345488 http://dx.doi.org/10.3324/haematol.2023.283120

Ejemplares similares

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Allogeneic stem cell transplantation in acute myeloid leukemia
por: Ali, Natasha, et al.
Publicado: (2012)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Acute Myeloid Leukemia as a Model for Cancer Therapy
por: Ravandi, Farhad
Publicado: (2012)

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
por: Tettero, Jesse M., et al.
Publicado: (2023)

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
por: Hattori, Norimichi, et al.
Publicado: (2019)

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
por: Loke, Justin, et al.
Publicado: (2021)

Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Jing, et al.
Publicado: (2018)

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
por: Ball, Brian, et al.
Publicado: (2019)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Acute myeloid leukemia post-allogeneic peripheral stem cell transplant with gastric chloroma
por: Ur Rehman, Jalil, et al.
Publicado: (2011)

Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Facenda-Lorenzo, María, et al.
Publicado: (2016)

Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India
por: Ganapule, Abhijeet, et al.
Publicado: (2017)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Xuan, Li, et al.
Publicado: (2021)

Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
por: Kunadt, Desiree, et al.
Publicado: (2021)

Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities
por: Chen, Yong-Feng, et al.
Publicado: (2023)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
por: Pabon, Cindy M., et al.
Publicado: (2021)

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
por: Mangaonkar, Abhishek, et al.
Publicado: (2017)

A Survey of Infection in Allogenic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
por: Safayi, S. R., et al.
Publicado: (2018)

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
por: Rautenberg, Christina, et al.
Publicado: (2019)

Extramedullary Gastric Relapse of Acute Myeloid Leukemia After Allogenic Hematopoietic Stem Cell Transplantation
por: Hong, Ji-Yun, et al.
Publicado: (2020)

Oral complaints in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation
por: Wysocka-Słowik, Aleksandra, et al.
Publicado: (2021)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2023)

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Namdaroglu, Sinem, et al.
Publicado: (2019)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Morsink, Linde M., et al.
Publicado: (2020)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

Deferred autologous stem cell transplantation in systemic AL amyloidosis
por: Manwani, Richa, et al.
Publicado: (2018)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia
por: Norkin, Maxim, et al.
Publicado: (2017)

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Kong, Jun, et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
por: Lipof, Jodi J., et al.
Publicado: (2018)

Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?
por: Ganser, Arnold
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o8n75atj2bnvn42hbsv9iiao2r